Synonym
Ninerafaxstat trihydrochloride; Ninerafaxstat 3HCl; Ninerafaxstat HCl; Ninerafaxstat hydrochloride; CV 8972; CV-8972; CV8972; IMB-1018972; IMB 1018972; IMB1018972; IMB-101;
IUPAC/Chemical Name
2-(4-(2,3,4-trimethoxybenzyl)piperazin-1-yl)ethyl nicotinate trihydrochloride
InChi Key
XDBODYSZDLGFRQ-UHFFFAOYSA-N
InChi Code
1S/C22H29N3O5.3ClH/c1-27-19-7-6-18(20(28-2)21(19)29-3)16-25-11-9-24(10-12-25)13-14-30-22(26)17-5-4-8-23-15-17;;;/h4-8,15H,9-14,16H2,1-3H3;3*1H
SMILES Code
Cl.Cl.Cl.COc1ccc(CN2CCN(CCOC(=O)c3cccnc3)CC2)c(OC)c1OC
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
524.86
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Whiteson HZ, Grossman SH, Whiteson EM, Frishman WH. Ninerafaxstat in the Treatment of Cardiometabolic Disease: Shifting Metabolic Paradigms. Cardiol Rev. 2024 May 16. doi: 10.1097/CRD.0000000000000719. Epub ahead of print. PMID: 38752753.
2: Lim GB. Benefits of ninerafaxstat in non-obstructive hypertrophic cardiomyopathy. Nat Rev Cardiol. 2024 Jun;21(6):357. doi: 10.1038/s41569-024-01032-y. PMID: 38654087.
3: Maron MS, Mahmod M, Abd Samat AH, Choudhury L, Massera D, Phelan DMJ, Cresci S, Martinez MW, Masri A, Abraham TP, Adler E, Wever-Pinzon O, Nagueh SF, Lewis GD, Chamberlin P, Patel J, Yavari A, Dehbi HM, Sarwar R, Raman B, Valkovič L, Neubauer S, Udelson JE, Watkins H. Safety and Efficacy of Metabolic Modulation With Ninerafaxstat in Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)06684-1. doi: 10.1016/j.jacc.2024.03.387. Epub ahead of print. PMID: 38599256.
